Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis

To the Editors:

Infliximab is a chimeric human-mouse anti-tumour necrosis factor-α (anti-TNF-α) immunoglobulin G monoclonal antibody that binds the soluble and transmembrane forms of TNF-α. Its efficacy in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis (RA) and Crohn's disease, is well documented 1, 2, and recent reports indicate a possible use in the treatment of psoriasis, giant cell arteritis, spondyloarthropaties and sarcoidosis 3–6.

As conventional treatments of idiopathic pulmonary fibrosis and lung fibrosis associated …